'Buy' Sun Pharma Shares Maintains Nirmal Bang, Says India, Specialty To Drive Growth

While near-term headwinds such as elevated marketing expenses, rising tax rates, and persistent pricing pressure in the U.S. generics business have led the brokerage to tweak its estimates, thus remains constructive on Sun Pharma’s long-term fundamentals.